Bromodeoxyuridine (300 mg/kg, i.p. or 0.8 mg/mL, p.o.) significantly slows tumor progression in rat glioma RG2 tumor model[1].
In Vitro
Bromodeoxyuridine induces a progressive, dose-responsive suppression of cancer cell line and cancer stem cell population expansion RG2 rat glioma cells. In H9 cells and BJ fibroblasts, bromodeoxyuridine alters the cell cycle profile[1]. BrdU is stably integrated into the DNA, and thus can be used in assessment of cell proliferation and other cell procession[2].
Kinase Assay
Cell Assay
Cultures are initially plated at 2000 cells/cm2 and are quantified with a Z2 Coulter Counter. RG2 rat glioma cells are treated once with 0, 1, 10, or 50 µM BrdU for 24 hours, and cumulative growth curves are obtained over 18 days. Control and treated cells are quantified and replated at equal densities on days 5, 12, and 18 after treatment.
Animal Administration
References
[1]. Levkoff LH, et al. Bromodeoxyuridine inhibits cancer cell proliferation in vitro and in vivo. Neoplasia. 2008 Aug;10(8):804-16.
[2]. Rothaeusler K, et al. Assessment of cell proliferation by 5-bromodeoxyuridine (BrdU) labeling for multicolor flow cytometry. Curr Protoc Cytom. 2007 Apr;Chapter 7:Unit7.31
Return Policy
If you are in any way unsatisfied with your purchase, you may return any item(s) within 365 days of its original purchase date.
Please provide your Order Number in the email. We strive to reply to all email inquiries within one business day.
